Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease

BACKGROUND AND OBJECTIVES: Use of parenteral amikacin to treat refractory nontuberculous mycobacterial (NTM) lung disease is limited by systemic toxicity. A population pharmacokinetic model was developed using data pooled from two randomized trials to evaluate the pharmacokinetic properties of once-...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Eur J Drug Metab Pharmacokinet
Main Authors: Rubino, Christopher M., Onufrak, Nikolas J., van Ingen, Jakko, Griffith, David E., Bhavnani, Sujata M., Yuen, Dayton W., Mange, Kevin C., Winthrop, Kevin L.
Formato: Artigo
Idioma:Inglês
Publicado: Springer International Publishing 2021
Assuntos:
Original Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7935831/
https://ncbi.nlm.nih.gov/pubmed/33595792
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13318-020-00669-7
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares